Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Oct 29, 2022 8:02pm
237 Views
Post# 35058121

So, that's Q2...

So, that's Q2...What's next?

I think that the AGM agenda could be very interesting.

Is everybody on the BoD still running?

Is Bioasis going to ask for a green light to do whatever TF they want to do?

Will Lind lend the money to Bioasis that it needs?

How much?

What does the amount mean?

A little - deals coming.

A lot - no deals coming.

Consolidation? How much pain?

With no deals, which means no real accomplishments, is NASDAQ a realistic goal?

Is Bioasis all about xB3? Or is Cresence all that has value?

Never (NEVER !!) has Bioasis been at the crossroads like this.

And what about that careless (or maybe intentional) leak at xB3-001 at the Vancouver roadshow in June? Is Bioasis really going to raise money to move xB3-001 forward, as indicated in the filings, or is there a partner, named in June, who is going to do that?

Come on, beenthere, MT, Frt and pof. Tell us what to expect next from Bi Oh Aye Sys?

I think DrDR is all about hiding, and hiding, and hiding, and then exposing when shareholders can't do a thing about it.

But I guess we'll see.

Go Phillies!

jd
<< Previous
Bullboard Posts
Next >>